Avidity Biosciences CMO Exercises Options, Sells Shares

Rhea-AI Filing Summary

Avidity Biosciences, Inc. Chief Medical Officer Steven George Hughes exercised a stock option for 1,542 shares of common stock at $6.57 per share on August 13, 2025, then sold those 1,542 shares at $46.66 per share pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2024. After these transactions he directly holds 38,867 common shares and retains 50,875 stock options expiring in 2033.

Insights

Corporate Governance Expert

TL;DR: Officer used a Rule 10b5-1 plan to sell shares after exercising vested option tranche; disclosure is consistent with standard governance practice.

The Form 4 shows a transparent, pre‑planned sale under a Rule 10b5-1 trading plan adopted 06/12/2024, which helps insulate the officer from insider-trading allegations. The filing discloses both the exercise of a tranche of options and the concurrent sale of the same number of shares, and reports the resulting change in direct beneficial ownership from 40,409 to 38,867 shares. Nothing in the filing indicates deviation from the plan or other governance concerns based on the disclosed facts.

Securities Analyst

TL;DR: The transaction is a routine option exercise and market sale under a 10b5-1 plan, producing a modest reduction in insider holdings.

The reporting shows exercise of 1,542 option shares (exercise price $6.57) and immediate sale of 1,542 common shares for $46.66 each on 08/13/2025. The option grant date (09/11/2023) and vesting schedule (monthly tranches ending 09/11/2027) are disclosed, allowing investors to track future potential exercises and sales tied to vesting. Based solely on disclosed items, this is a routine liquidity event rather than a material corporate development.

Insider Trade Summary

Exercise and Sale: 1,542 shares ($62K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Hughes Steven George

Role Chief Medical Officer

Sold 1,542 shs ($72K)

Approx. gross sale proceeds $72K

Approx. exercise cost $10K

Approx. pre-tax spread $62K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	1,542	$0.00	$0.00
Exercise	Common Stock	1,542	$6.57	$10K
Sale	Common Stock	1,542	$46.66	$72K

Holdings After Transaction: Stock Option (Right to Buy) — 50,875 contracts (Direct); Common Stock — 38,867 shares (Direct)

Footnotes (2)

1. F1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024.
2. F2. This option was granted on September 11, 2023 and vests in equal installments of 1,542 shares on each monthly anniversary of such grant date, until it is fully vested and exercisable on September 11, 2027.

Key Figures

Shares exercised: 1,542 shares Exercise price: $6.57 per share Shares sold: 1,542 shares +4 more

7 metrics

Shares exercised 1,542 shares Stock option exercise into common stock on August 13, 2025 at $6.57 per share

Exercise price $6.57 per share Conversion of Stock Option (Right to Buy) into 1,542 common shares

Shares sold 1,542 shares Common stock sold on August 13, 2025 at $46.66 per share

Sale price $46.66 per share Open-market or private sale of 1,542 common shares by the CMO

Post-transaction common shares 38,867 shares Direct common stock holdings after the reported transactions

Options remaining 50,875 options Stock options held following the exercise, expiring September 10, 2033

Option grant vesting 1,542 shares monthly Option granted September 11, 2023 vests in equal monthly installments until September 11, 2027

Key Terms

Rule 10b5-1 trading plan, Stock Option (Right to Buy), vests in equal installments

3 terms

Rule 10b5-1 trading plan regulatory

"The sales reported were effected pursuant to a Rule 10b5-1 trading plan previously adopted."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Stock Option (Right to Buy) financial

"Security title identified as Stock Option (Right to Buy) with an exercise price of $6.57."

vests in equal installments financial

"This option was granted and vests in equal installments of 1,542 shares on each monthly anniversary."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Avidity Biosciences (RNA) CMO Steven Hughes report in this Form 4?

Steven Hughes reported exercising options for 1,542 shares of Avidity Biosciences common stock at $6.57 per share, then selling those 1,542 shares at $46.66 per share on August 13, 2025, under a Rule 10b5-1 trading plan.

How many Avidity Biosciences (RNA) shares does the CMO hold after the transactions?

After the reported option exercise and share sale, Steven Hughes directly holds 38,867 shares of Avidity Biosciences common stock. He also retains 50,875 stock options with a $6.57 exercise price and a 2033 expiration date.

At what prices did the Avidity Biosciences (RNA) CMO exercise and sell shares?

Steven Hughes exercised stock options at an exercise price of $6.57 per share and sold the resulting 1,542 common shares at $46.66 per share on August 13, 2025, as disclosed in the Form 4.

Was the Avidity Biosciences (RNA) insider sale made under a Rule 10b5-1 plan?

Yes. A footnote states the sales reported were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Steven Hughes on June 12, 2024, indicating the trades were pre-arranged under that plan.

What are the terms of the Avidity Biosciences (RNA) stock option involved?

The option was granted on September 11, 2023 at an exercise price of $6.57 per share. It vests in equal installments of 1,542 shares monthly until fully vested and exercisable on September 11, 2027, and expires in 2033.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/15/2025 - 04:07 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hughes Steven George

(Last) (First) (Middle)

C/O AVIDITY BIOSCIENCES, INC.

10578 SCIENCE CENTER DRIVE, SUITE 125

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Avidity Biosciences, Inc. [ RNA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/13/2025		M(1)		1,542	A	$6.57	40,409	D
Common Stock	08/13/2025		S(1)		1,542	D	$46.66	38,867	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$6.57	08/13/2025		M(1)			1,542	(2)	09/10/2033	Common Stock	1,542	$0	50,875	D

Explanation of Responses:

1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024.

2. This option was granted on September 11, 2023 and vests in equal installments of 1,542 shares on each monthly anniversary of such grant date, until it is fully vested and exercisable on September 11, 2027.

Remarks:

	/s/ John B. Moriarty, Jr., J.D., Attorney-in-Fact	08/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.